Boston Scientific (BSX) ended the recent trading session at $64.61, demonstrating a +1.24% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.8%. Meanwhile, the Dow lost 0.15%, and the Nasdaq, a tech-heavy index, added 1.6%.
Coming into today, shares of the medical device manufacturer had lost 10.37% in the past month. In that same time, the Medical sector lost 0.77%, while the S&P 500 gained 5.15%.
Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to go public on April 22, 2026. The company is predicted to post an EPS of $0.8, indicating a 6.67% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $5.19 billion, showing a 11.2% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.45 per share and a revenue of $22.28 billion, signifying shifts of +12.75% and +10.99%, respectively, from the last year.
Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.14% lower. Boston Scientific is currently a Zacks Rank #3 (Hold).
Looking at its valuation, Boston Scientific is holding a Forward P/E ratio of 18.5. This signifies a discount in comparison to the average Forward P/E of 19.49 for its industry.
We can additionally observe that BSX currently boasts a PEG ratio of 0.99. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 1.64.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 165, placing it within the bottom 33% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).